Clinical Trials in San Francisco

Showing 5041-5060 of 9,883 trials

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

NCT02772679

The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.

Type 1 Diabetes Mellitus

Jeffrey Bluestone16 participantsStarted Aug 2016

San Francisco, California, United States • New Haven, Connecticut, United States

COMPLETEDPhase 1< 1 mile

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

NCT01479296

The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)90 participantsStarted Dec 2011

San Francisco, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +5 more locations

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

Find Trials by Condition in San Francisco

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

Study of AMV564 in Patients With AML

Effect of Efpeglenatide on Cardiovascular Outcomes

A Pilot Evaluation of the Insomnia Coach Mobile App

Convalescent Plasma in Outpatients With COVID-19

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine